| Document |
Document Title |
|
WO/2024/102006A1 |
There is provided a flow control apparatus comprising a delivery tube having a lumen, the delivery tube extending along a longitudinal axis within a housing to a focussing chamber; one or more channels defined between an external surface...
|
|
WO/2024/081673A3 |
The present disclosure provides, among other things, systems, engineered cell lines and methods of manufacturing recombinant viral vectors and products. Engineered cell lines comprise one, two, three, or more stably integrated genomic co...
|
|
WO/2024/102965A1 |
Disclosed herein are designer extracellular vesicles (EVs) that target muscle cells. For example, in some embodiments, the EVs are decorated NHERF1, NHERF2, a fusion protein containing an E8 fragment of laminin and an exosomal or lysosom...
|
|
WO/2024/099320A1 |
A hybrid protein containing a CFH functional unit and a DAF functional unit, and a mutant thereof, an encoding nucleic acid thereof, and a method and the use thereof for treating diseases or conditions related to a complement system; and...
|
|
WO/2024/044750A3 |
The present disclosure features allogeneic modified cells (e.g., T- or NK-cells) having increased persistence, increased resistance to immune rejection, or decreased risk of eliciting a host-versus-graft reaction, or a combination thereo...
|
|
WO/2024/100229A1 |
The invention relates to a method of manufacturing an edible food product comprising edible protein threads embedded in a fatty matrix, said method comprising the following steps: - Preparing a protein matrix (130), said protein matrix c...
|
|
WO/2024/101962A1 |
The present invention relates to cells that have been genetically engineered to express a peptide or fragment thereof capable of inhibiting the transforming growth factor-β (TGF-β) signaling pathway, in conjunction with a chimeric anti...
|
|
WO/2024/100557A1 |
Provided are glycoprotein NMB (GPNMB)-binding chimeric antigen receptors (CARs). In some embodiments, a CAR of the present disclosure comprises an extracellular GPNMB-binding domain (e.g., a single chain antibody, such as an scFv), a tra...
|
|
WO/2024/101323A1 |
The present disclosure pertains to a method for producing a cell population, the method comprising: a step for separating cells from a three-dimensional tissue body formed in vitro and containing the cells and an extracellular matrix com...
|
|
WO/2024/103049A1 |
Disclosed are exosomes comprising an extracellular CD33 binding motif fused to a transmembrane protein. Disclosed are methods of making a cell derived exosome comprising: transfecting a plasmid into cells, wherein the plasmid comprises a...
|
|
WO/2024/102604A1 |
Anti-5T4 antibodies and antigen-binding fragments thereof and chimeric antigen receptors (CARs) comprising anti-5T4 antigen-binding domains are described. Also described are nucleic acids encoding the antibodies and CARs, compositions co...
|
|
WO/2024/102979A2 |
A cell centrifugation consumable and a method of using the cell centrifugation consumable is disclosed. The cell centrifugation consumable includes an inner fluid chamber configured to hold cells during centrifugation and a decanting spa...
|
|
WO/2024/006281A3 |
The present disclosure pertains to modified immune cells comprising chimeric switch receptors and methods of using and making immune cells comprising chimeric switch receptors. The present disclosure also pertains to modified immune cell...
|
|
WO/2024/098361A1 |
The present application relates to the technical field of bio-pharmaceuticals. The present application particularly relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3'-untranslate...
|
|
WO/2024/064640A3 |
Disclosed herein are chimeric antigen receptors (CARs) comprising an antigen binding site that recognizes citrullinated polypeptides. Citru llinated polypeptides, such as citrullinated vimentin, are expressed in the skin lesions of subje...
|
|
WO/2024/100604A1 |
Provided herein are methods for producing genetically engineered immune cells, such as T cells. In some aspects, the immune cells are genetically engineered by targeted integration of a transgene into a target site of a gene in the immun...
|
|
WO/2024/076910A3 |
Organoid culture and image-processing methods and systems are described. Such methods and systems provide the ability for high-throughput characterization of a variety of phenotypes at single-organoid resolution.
|
|
WO/2024/096707A1 |
The present invention relates to: a composition for preventing or treating Moyamoya disease, comprising, as an active ingredient, miRNAs or extracellular vesicles comprising same; and a composition for preventing or treating Moyamoya dis...
|
|
WO/2024/097901A1 |
. Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional...
|
|
WO/2024/097904A1 |
This disclosure provides, among other things, an engineered immunosuppressive (e.g., CD4+) T cell comprising a molecular circuit comprising the following components: (a) a central nervous system (CNS)-specific binding-triggered transcrip...
|
|
WO/2024/092339A1 |
A hybrid microgel, comprising a thermoresponsive polymer, and a polysaccharide comprising amorphous domains, the thermoresponsive polymer being grafted to the polysaccharide; methods of making the hybrid microgel, and compositions useful...
|
|
WO/2024/097315A2 |
Methods of profiling cells for donor capability with a recipient subject are provided. In particular, methods relating to identifying cells, such as T cells, suitable for making a cell therapy product and administration to a patient (e.g...
|
|
WO/2024/096090A1 |
Disclosed is a microphysiological system comprising a microfluidic device, and human renal proximal tubular epithelial cells (RPTEC) and pluripotent stem cell-derived LTL-positive cells which are accommodated in the microfluidic device. ...
|
|
WO/2024/096138A1 |
This culture device comprises a container body that houses a culture liquid, and a culture chip that forms a culture chamber inside the container body, wherein: the container body has a light-permeable and gas-permeable bottom wall; and ...
|
|
WO/2024/092343A1 |
A cell culture bioreactor has hollow fiber membranes within an extra-capillary space optionally used to grow cells in suspension. The membranes may include liquid perfusion membranes and/or gas transfer membranes. Liquid medium moves wit...
|
|
WO/2024/097637A1 |
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a human BRAFV600E amino acid sequence. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression ...
|
|
WO/2024/097655A1 |
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated amino acid sequence encoded by mutated CDKN2A. The TCRs may recognize mutated CDKN2A peptide presented by an HLA-A molecu...
|
|
WO/2024/097800A1 |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional g...
|
|
WO/2024/097276A1 |
This document relates to methods and materials involved in treating cancer. For example, methods and materials for using chimeric antigen receptor (CAR) T cells having reduced levels of an interleukin (IL) 4 polypeptide, having reduced l...
|
|
WO/2024/093652A1 |
The present invention discloses a nanobody targeting IL-6Rα protein and uses thereof, wherein the heavy chain variable region of the nanobody comprises three complementary determining regions, CDR1, CDR2, and CDR3, wherein CDR1 has an a...
|
|
WO/2024/092375A1 |
The invention discloses a method for preparing a composition of mitochondria isolated from umbilical cord mesenchymal stromal cells (UC-MSC) and enriched with mitochondrial antiviral-signalling (MAVS) protein, and the use of this composi...
|
|
WO/2024/097814A1 |
The invention provides methods for upregulating mitochondrial and/or glycolytic metabolism in T cells by increasing the flux of pyruvate into the citric acid cycle, thereby increasing mitochondrial and/or glycolytic metabolism. In genera...
|
|
WO/2024/097900A1 |
RNA molecules comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-2325 and compositions, methods, and uses thereof.
|
|
WO/2024/097892A1 |
This disclosure relates to introducing specified endogenous amiRNA responsive to endogenous primary-miRNAs. This invention allows the degradation of amiRNAs in specific tissues, while allowing amiRNA to silence gene expression in other t...
|
|
WO/2024/093790A1 |
The present application relates to the field of biotechnology, and in particular, to a stable and high-yield targeted integration cell, a method for preparing same, and use thereof. Compared with conventional techniques, the present appl...
|
|
WO/2024/094159A1 |
Provided in the present application are a single domain antibody targeting the ROR1 protein as well as a chimeric antigen receptor (CAR) and CAR-T cell comprising the single domain antibody. Also provided are uses of the single domain an...
|
|
WO/2024/098019A1 |
The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem/progenitor cell transplant. For example, the present disclosure provides a therapeutic populati...
|
|
WO/2024/094017A1 |
Provided are a GPC3 bispecific antigen binding molecule or an antigen binding fragment thereof, a derivative containing the bispecific antigen binding molecule or the antigen binding fragment thereof, and a pharmaceutical composition. In...
|
|
WO/2024/098024A1 |
Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetic...
|
|
WO/2024/094165A1 |
A B7H3 binding polypeptide, comprising two different anti-B7H3 single domain antibodies. The present invention further relates to a chimeric antigen receptor comprising the B7H3 binding polypeptide, and a universal CAR-T cell comprising ...
|
|
WO/2024/098037A1 |
The present disclosure provides chimeric receptor constructs comprising a CD3e extracellular domain and engineered NK and T cells expressing such receptors and methods of making and using same for the treatment of cancer and other diseas...
|
|
WO/2024/097738A1 |
A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiven...
|
|
WO/2024/098036A1 |
The subject matter described here relates to anti -PAG antibodies. The subject matter described here also provides a pharmaceutical composition of, or a kit for generating an anti-PAG antibody; a method of making an anti-PAG antibody; a ...
|
|
WO/2024/096120A1 |
The present disclosure relates to improving the colonization properties of a bacterial preparation in a host. Specifically, the present disclosure relates to a microorganism wherein at least one gene is modified, said modification improv...
|
|
WO/2024/093147A1 |
The present invention relates to an antibody specifically binding to the v5 exon of human CD44 or a fragment thereof. The present invention also relates to a chimeric antigen receptor molecule comprising the antibody or the fragment ther...
|
|
WO/2024/095599A1 |
Provided is a method for producing glomus cell-like cells, the method including: (a) a step for inducing differentiation of pluripotent stem cells into autonomic progenitor cells; and (b) a step for culturing the autonomic progenitor cel...
|
|
WO/2024/096506A1 |
The present invention relates to a method for preparing a high-concentration liquid medium having reduced osmotic pressure, and a method for producing a protein of interest by using the medium. When the high-concentration liquid medium i...
|
|
WO/2024/097911A1 |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional g...
|
|
WO/2024/096009A1 |
The purpose of the present invention is to provide sperm having high motility. The present invention is a sperm treatment composition that contains an exosome. A sperm treatment composition according to the present invention is used as a...
|
|
WO/2024/092300A1 |
The present disclosure relates to methods for differentiating mesenchymal stem cells (MSCs) towards an osteogenic lineage using daily short exposure to acoustic wave energy at a frequency greater than 1MHz. Methods disclosed herein can b...
|
